<DOC>
	<DOCNO>NCT01434069</DOCNO>
	<brief_summary>This single-arm , open-label , phase I study combination therapy SOM 230 FOLFIRI . We utilize sequential dose-escalation design define maximum tolerate dose ( MTD ) SOM 230 combine standard dos FOLFIRI .</brief_summary>
	<brief_title>Phase I Trial Combination FOLFIRI SOM 230</brief_title>
	<detailed_description>The goal clinical research study learn study drug SOM 230 , also know Pasireotide long-acting release ( LAR ) , addition standard therapy FOLFIRI ( 5FU , leucovorin , irrinotecan ) shrink slow growth gastrointestinal malignancy . The safety drug combination standard chemotherapy ( FOLFIRI ) also study . The participant 's physical state , change size tumor , laboratory finding take on-study help u decide Pasireotide LAR safe effective .</detailed_description>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<criteria>Histologically proven metastatic/unresectable gastrointestinal malignancy ( colon , small bowel , pancreas , gastric esophageal cancer , etc . ) amenable curative surgical therapy , FOLFIRI consider standard treatment Have least 1 prior treatment GI tumor except small bowel adenocarcinoma FOLFIRI consider standard first line therapy particular tumor . Measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) criteria ≥ 4 week since major surgery , completion radiation , completion prior systemic anticancer therapy ( adequately recover acute toxicity prior therapy ) Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Adequate bone marrow function show : absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L , Platelets ≥ 100 x 10^9/L , hemoglobin ( Hgb ) &gt; 9 g/dL Adequate liver function show : serum bilirubin ≤ 2 x upper limit normal ( ULN ) , serum transaminase activity ≤ 3 x ULN Adequate renal function show serum creatinine ≤ 1.5 x ULN Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fast triglyceride ≤ 2.5 x ULN . Note : In case one threshold exceed , patient include initiation appropriate lipid lower medication . Women childbearing potential ( WOCBP ) must negative serum pregnancy test within 14 day administration first study treatment . Women must lactate . Signed informed consent participate study must obtain patient fully inform nature potential risk investigator ( his/her designee ) aid write information Prior treatment irinotecan . Irinotecan radiation allow &gt; 4 week . Any cytotoxic chemotherapy , radiation , immunotherapy , investigational drug within precede 3 week start study treatment History liver disease , cirrhosis chronic active hepatitis B C History , current alcohol misuse/abuse within past 12 month Known gallbladder bile duct disease , ( ie infection cholecystitis ) acute chronic pancreatitis Have undergone major surgery within 4 week prior study enrollment Uncontrolled brain leptomeningeal metastasis , include patient continue require glucocorticoid brain leptomeningeal metastasis . Patients treat least 4 week prior enrollment , compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) brain within 4 week enrollment , show evidence progression disease brain , allow enroll . Patients uncontrolled diabetes mellitus define hemoglobin A1c ( HbA1c ) &gt; 8 % despite therapy fast plasma glucose &gt; 1.5 ULN . Note : At principal investigator 's discretion , noneligible patient rescreened adequate medical therapy institute . Symptomatic cholelithiasis Have congestive heart failure : New York Heart Association ( NYHA ) Class III IV unstable angina History syncope family history idiopathic sudden death Sustained clinically significant cardiac arrhythmia include sustain ventricular tachycardia , ventricular fibrillation , clinically significant bradycardia , advanced heart block ( Mobitz II high atrioventricular nodal block AV ) ) , patient prolong correct QT interval ( QTc ) ( longer 470 millisecond ) history acute myocardial infarction within 6 month precede enrollment . ( The `` QT interval '' time start Q wave end T wave cardiac electrical cycle . The `` QTc '' QT interval correct heart rate . ) Risk factor Torsades de Pointes hypokalemia , hypomagnesemia , cardiac failure , clinically significant/symptomatic bradycardia , highgrade AV block Concomitant disease ( ) could prolong QT autonomic neuropathy ( cause diabetes Parkinson 's disease ) , human immunodeficiency virus ( HIV ) , cirrhosis , uncontrolled hypothyroidism cardiac failure Patients find sustained ventricular tachycardia , ventricular fibrillation , advanced heart block ( Mobitz II high AV nodal block ) , prolong QTc ( average longer 470 millisecond ) holter monitor screening time . ( applies patient cohorts 60 mg SOM 230 high ) Concomitant medication ( ) know prolong QT interval ( patient must drug 2 week eligible ) Presence active suspect acute chronic uncontrolled infection history immunocompromise , include positive HIV test result Any severe and/or uncontrolled medical condition condition could affect participation study : Severely impaired lung function ; Any active ( acute chronic ) uncontrolled infection/ disorder ; Nonmalignant medical illness uncontrolled whose control may jeopardize treatment study therapy Known suspect allergy hypersensitivity component FOLFIRI , somatostatin analogue component pasireotide octreotide long act release ( LAR ) formulations No active malignancy except nonmelanoma skin cancer situ cervical cancer treat cancer patient continuously disease free 5 year Women pregnant breast feeding , women/men able conceive unwilling practice effective method birth control . WOCBP must negative serum pregnancy test within 14 day prior administration pasireotide . Oral , implantable , injectable contraceptive may affect cytochrome P450 interaction , therefore consider effective study Unwilling unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>colon</keyword>
	<keyword>rectum</keyword>
	<keyword>small bowel</keyword>
	<keyword>pancreas</keyword>
	<keyword>gastric</keyword>
	<keyword>esophageal</keyword>
	<keyword>metastatic</keyword>
	<keyword>unresectable</keyword>
	<keyword>GI</keyword>
	<keyword>combination therapy</keyword>
	<keyword>dose escalation</keyword>
	<keyword>solid tumor</keyword>
</DOC>